Home / Themes / Biotech '26: Established Pharma
Biotech '26: Established Pharma Watchlist (view performance)
Last updated
Theme thesis · 3/5 sections · Tickers 2 with notes · 8 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Bull / Bear DetailsAs of Spring 2025, the thesis for the Biotech '24: Established Pharma subtheme is mixed. While established pharmaceutical companies like RHHBY, VRTX, REGN, NTRA
No data for this section.
Key Metrics
| Metric | Cadence | What It Signals | Update Source |
|---|---|---|---|
| R&D Spending Trends | Quarterly | Reflects commitment to innovation and future pipeline strength. | Google_Sheets |
| Competitive Pipeline Developments | Monthly | Tracks new entrants and competitive threats in the market. | Google_Sheets |
| Drug Approval Rates | Quarterly | Indicates regulatory success and potential revenue growth. | Google_Sheets |
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| ABT_e32745b9 | in the third quarter | 2026-07-01 | 2026-09-30 | Transition from limited market release to full market release of the Bolt 2.0 PFA catheter in the US. | This full market release is expected to accelerate Abbott's growth trajectory and help the company outperform the market and recapture share in the electrophysiology segment. | Ticker | 2026-07-16 | earnings_transcript | ABT (ticker) |
| JNJ_31eabe8e | during the third quarter of 2026 | 2026-07-01 | 2026-09-30 | Close of Firefly Bio acquisition. | This acquisition strengthens JNJ's leadership in next-generation oncology innovation by adding a proprietary platform designed to target KRAS-driven solid tumors and further diversifying the oncology pipeline. | Ticker | 2026-07-15 | earnings_transcript | JNJ (ticker) |
| ABT_ba778762 | could happen in the fall | 2026-09-01 | 2026-11-30 | Medicare reimbursement expansion for continuous glucose monitoring (CGM) for Type 2 non-insulin users in the US. | This represents a multibillion-dollar opportunity, unlocking coverage for approximately 10 million Medicare beneficiaries and accelerating commercial insurance adoption, which is expected to significantly boost CGM sales. | Ticker | 2026-07-16 | earnings_transcript | ABT (ticker) |
| ABT_6009f906 | in the fall | 2026-09-01 | 2026-11-30 | International rollout of Libre Duo, the world's first dual glucose ketone monitoring sensor. | The introduction of this innovative new technology internationally is expected to contribute to the growth and leadership of Abbott's diabetes care business. | Ticker | 2026-07-16 | earnings_transcript | ABT (ticker) |
| ABT_30e24e43 | potential to be able to get this approved by year end | 2026-10-01 | 2026-12-31 | FDA approval for the new Amulet 360 left atrial appendage device. | This approval enables a significant relaunch of a superior product in the $2 billion LAA closure market, positioning Abbott for substantial market share capture in the electrophysiology business. | Ticker | 2026-07-16 | earnings_transcript | ABT (ticker) |